Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00856661 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 3
- Development phase
- 270
- Enrollment target
NCT00856661 is a Phase 3 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 270 participants.
The verdict
NCT00856661, a Phase 3 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 270 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3 to 9 hours from onset of stroke symptoms.
Interventions
- DRUG Placebo
- DRUG Desmoteplase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00856661
The ClinicalTrials.gov registry entry for NCT00856661 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00856661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00856661 about?
NCT00856661 is a clinical study titled "Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)". The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3 to 9 hours from onset of stroke symptoms.
What is the current status of trial NCT00856661?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 270 participants. The study started on 2009-04.
What interventions are being tested in trial NCT00856661?
The interventions under investigation include: Placebo (DRUG), Desmoteplase (DRUG).
Who is sponsoring clinical trial NCT00856661?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.